



## **Momenta Pharmaceuticals Announces Presentation of M402 Preclinical Data at Upcoming AACR Meeting**

CAMBRIDGE, Mass., Apr 15, 2010 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

The following two posters will be presented:

"M402 - A Novel Heparin Sulfate Mimetic Synergizes with Gemcitabine to Improve Survival and Reduce Metastasis and Epithelial-to-Mesenchymal Transition (EMT) in a Genetically Engineered Mouse Model for Pancreatic Cancer" (abstract #LB-43)

-- Poster Session: Sunday, April 18, 2010 from 2:00 PM - 5:00 PM

"M402 - A Novel Heparan Sulfate Proteoglycan Mimetic Targeting Tumor-Host Interactions" (abstract #2269)

-- Poster Session: Monday, April 19, 2010 from 2:00 PM - 5:00 PM

### **About Momenta**

Momenta Pharmaceuticals is a biotechnology company headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products as well as to the discovery and development of novel drugs. To receive additional information about Momenta, please visit the website at [www.momentapharma.com](http://www.momentapharma.com), which does not form a part of this press release.

This news release was distributed by GlobeNewswire, [www.globenewswire.com](http://www.globenewswire.com)

SOURCE: Momenta Pharmaceuticals

CONTACT: Momenta Pharmaceuticals, Inc.  
Beverly Holley  
617-395-5189  
[bholley@momentapharma.com](mailto:bholley@momentapharma.com)

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX